Accuracy of the Truenat MTB-RIF Dx assay for detection of rifampicin resistance-associated mutations

Tuberculosis (Edinb). 2021 Mar:127:102064. doi: 10.1016/j.tube.2021.102064. Epub 2021 Feb 19.

Affiliations

¹ Foundation for Innovative New Diagnostics, Geneva, Switzerland.
² Indian Council for Medical Research-National Institute for Research in Tuberculosis, Chennai, India.
³ Foundation for Innovative New Diagnostics -India, New Delhi, India.
⁴ Foundation for Innovative New Diagnostics, Geneva, Switzerland. Electronic address: [email protected].

PMID: 33652272
DOI: 10.1016/j.tube.2021.102064

No abstract available

Keywords: Analytical; Diagnostics; Point-of-care; Rifampicin resistance; Tuberculosis.

Publication types

Letter
Research Support, Non-U.S. Gov't
Validation Study

MeSH terms

Antibiotics, Antitubercular / therapeutic use
Bacterial Proteins / genetics*
DNA Mutational Analysis*
DNA-Directed RNA Polymerases / genetics*
Drug Resistance, Multiple, Bacterial / genetics*
Genotype
Humans
Microbial Sensitivity Tests*
Mutation*
Mycobacterium tuberculosis / drug effects
Mycobacterium tuberculosis / genetics*
Mycobacterium tuberculosis / pathogenicity
Point-of-Care Testing*
Predictive Value of Tests
Reproducibility of Results
Rifampin / therapeutic use
Tuberculosis, Multidrug-Resistant / diagnosis*
Tuberculosis, Multidrug-Resistant / drug therapy
Tuberculosis, Multidrug-Resistant / microbiology

Substances

Antibiotics, Antitubercular
Bacterial Proteins
rpoB protein, Mycobacterium tuberculosis
DNA-Directed RNA Polymerases
Rifampin